WS
LRMR icon

Wedbush Securities’s Larimar Therapeutics LRMR Stock Holding History

Wedbush Securities’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,086
Closed -$94K – 950
2019
Q4 		$94K Sell
7,086
-7,081
-50% -$67.7K 0.01% 930
2019
Q3 		$126K Buy
14,167
+7,792
+122% +$85.4K 0.01% 880
2019
Q2 		$91K Buy
6,375
+3,458
+119% +$92.1K 0.01% 911
2019
Q1 		$96K Buy
+2,917
New +$150K 0.01% 859
2016
Q4 		– Sell
-1,075
Closed -$43K – 862
2016
Q3 		$43K Buy
+1,075
New +$48.8K 0.01% 797

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wedbush Securities's LRMR Position: Q1 2020 in Review

Wedbush Securities sold out of Larimar Therapeutics (LRMR) in Q1 2020, closing a stake of 7,086 shares — an estimated $94K sold.

Wedbush Securities first reported a position in LRMR in Q3 2016 and held it in 5 quarters. The position peaked at $126K in Q3 2019. 42 funds tracked by Wall St. Rank hold LRMR as of Q1 2020.

  • Wedbush Securities reported no remaining Larimar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Wedbush Securities sold 7,086 Larimar Therapeutics shares in Q1 2020, an estimated $94K.
  • Wedbush Securities first reported a position in Larimar Therapeutics in Q3 2016 and held it in 5 quarters.
  • Wedbush Securities's Larimar Therapeutics position peaked at $126K in Q3 2019.
  • 42 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2020.

Based on Wedbush Securities's 13F filing for Q1 2020, filed 17 Apr 2020.